Cargando…

Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center

BACKGROUND: Eribulin improves survival in pre-treated HER2-negative advanced breast cancer (ABC). However, limited data exist on co-morbidities and central nervous system (CNS) efficacy. The purpose of this study was to review eribulin’s efficacy and safety in everyday clinical practice with special...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirvén, Milana Bergamino, Fernández-Ortega, Adela, Stradella, Agostina, Morilla, Idoia, Falo, Catalina, Vázquez, Silvia, Castany, Roser, Villanueva, Rafael, Recalde, Sabela, Pérez, Valentí Navarro, Gil-Gil, Miguel, Pernas, Sonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868802/
https://www.ncbi.nlm.nih.gov/pubmed/31753013
http://dx.doi.org/10.1186/s40360-019-0367-x
_version_ 1783472347018166272
author Sirvén, Milana Bergamino
Fernández-Ortega, Adela
Stradella, Agostina
Morilla, Idoia
Falo, Catalina
Vázquez, Silvia
Castany, Roser
Villanueva, Rafael
Recalde, Sabela
Pérez, Valentí Navarro
Gil-Gil, Miguel
Pernas, Sonia
author_facet Sirvén, Milana Bergamino
Fernández-Ortega, Adela
Stradella, Agostina
Morilla, Idoia
Falo, Catalina
Vázquez, Silvia
Castany, Roser
Villanueva, Rafael
Recalde, Sabela
Pérez, Valentí Navarro
Gil-Gil, Miguel
Pernas, Sonia
author_sort Sirvén, Milana Bergamino
collection PubMed
description BACKGROUND: Eribulin improves survival in pre-treated HER2-negative advanced breast cancer (ABC). However, limited data exist on co-morbidities and central nervous system (CNS) efficacy. The purpose of this study was to review eribulin’s efficacy and safety in everyday clinical practice with special focus on age, body mass index (BMI) and central nervous system (CNS) activity. METHODS: An observational study was conducted in a series of HER2-negative ABC patients treated from January’14-December’17 outside a clinical trial. Objective Response Rate (ORR), Progression Free Survival (PFS), Overall Survival (OS), and association of clinical and pathological variables with outcome were evaluated. RESULTS: Ninety-five women were treated with at least one cycle of eribulin. Median age was 57 (33–83), and 18% were obese. Median number of prior chemotherapies for ABC was 3 (2–5) and 76% of patients had visceral metastases, including 21% with CNS involvement. Most tumors were estrogen receptor-positive (79%). ORR and stable disease (SD) at 6 months were 26.2 and 37.5%, respectively. Remarkably, relevant CNS efficacy was observed with eribulin: 20% of patients obtained partial response and 25% SD. Treatment was generally well tolerated and manageable, with 29% grade 3 and 10.9% grade 4 toxicities. Median PFS and OS were 4.1 months (CI95% 3.2–4.9) and 11.1 months (CI95% 9.5–14.7), respectively. Triple-negative disease, > 2organs involved and being younger than 70 years old were independent prognosis factors for worse OS in multivariate analysis. Most patients (75%) progressed in pre-existing metastases sites. CONCLUSION: In everyday clinical practice, eribulin’s efficacy seems similar to pivotal trials. CNS-efficacy was observed. TNBC, > 2 organs involved and being younger than 70 years old were independent prognosis factors for worse OS. Remarkably, less incidence of grade 4-toxicity compared to previous studies was found.
format Online
Article
Text
id pubmed-6868802
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68688022019-12-12 Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center Sirvén, Milana Bergamino Fernández-Ortega, Adela Stradella, Agostina Morilla, Idoia Falo, Catalina Vázquez, Silvia Castany, Roser Villanueva, Rafael Recalde, Sabela Pérez, Valentí Navarro Gil-Gil, Miguel Pernas, Sonia BMC Pharmacol Toxicol Research Article BACKGROUND: Eribulin improves survival in pre-treated HER2-negative advanced breast cancer (ABC). However, limited data exist on co-morbidities and central nervous system (CNS) efficacy. The purpose of this study was to review eribulin’s efficacy and safety in everyday clinical practice with special focus on age, body mass index (BMI) and central nervous system (CNS) activity. METHODS: An observational study was conducted in a series of HER2-negative ABC patients treated from January’14-December’17 outside a clinical trial. Objective Response Rate (ORR), Progression Free Survival (PFS), Overall Survival (OS), and association of clinical and pathological variables with outcome were evaluated. RESULTS: Ninety-five women were treated with at least one cycle of eribulin. Median age was 57 (33–83), and 18% were obese. Median number of prior chemotherapies for ABC was 3 (2–5) and 76% of patients had visceral metastases, including 21% with CNS involvement. Most tumors were estrogen receptor-positive (79%). ORR and stable disease (SD) at 6 months were 26.2 and 37.5%, respectively. Remarkably, relevant CNS efficacy was observed with eribulin: 20% of patients obtained partial response and 25% SD. Treatment was generally well tolerated and manageable, with 29% grade 3 and 10.9% grade 4 toxicities. Median PFS and OS were 4.1 months (CI95% 3.2–4.9) and 11.1 months (CI95% 9.5–14.7), respectively. Triple-negative disease, > 2organs involved and being younger than 70 years old were independent prognosis factors for worse OS in multivariate analysis. Most patients (75%) progressed in pre-existing metastases sites. CONCLUSION: In everyday clinical practice, eribulin’s efficacy seems similar to pivotal trials. CNS-efficacy was observed. TNBC, > 2 organs involved and being younger than 70 years old were independent prognosis factors for worse OS. Remarkably, less incidence of grade 4-toxicity compared to previous studies was found. BioMed Central 2019-11-21 /pmc/articles/PMC6868802/ /pubmed/31753013 http://dx.doi.org/10.1186/s40360-019-0367-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Sirvén, Milana Bergamino
Fernández-Ortega, Adela
Stradella, Agostina
Morilla, Idoia
Falo, Catalina
Vázquez, Silvia
Castany, Roser
Villanueva, Rafael
Recalde, Sabela
Pérez, Valentí Navarro
Gil-Gil, Miguel
Pernas, Sonia
Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center
title Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center
title_full Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center
title_fullStr Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center
title_full_unstemmed Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center
title_short Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center
title_sort real-world efficacy and safety of eribulin in advanced and pretreated her2-negative breast cancer in a spanish comprehensive cancer center
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868802/
https://www.ncbi.nlm.nih.gov/pubmed/31753013
http://dx.doi.org/10.1186/s40360-019-0367-x
work_keys_str_mv AT sirvenmilanabergamino realworldefficacyandsafetyoferibulininadvancedandpretreatedher2negativebreastcancerinaspanishcomprehensivecancercenter
AT fernandezortegaadela realworldefficacyandsafetyoferibulininadvancedandpretreatedher2negativebreastcancerinaspanishcomprehensivecancercenter
AT stradellaagostina realworldefficacyandsafetyoferibulininadvancedandpretreatedher2negativebreastcancerinaspanishcomprehensivecancercenter
AT morillaidoia realworldefficacyandsafetyoferibulininadvancedandpretreatedher2negativebreastcancerinaspanishcomprehensivecancercenter
AT falocatalina realworldefficacyandsafetyoferibulininadvancedandpretreatedher2negativebreastcancerinaspanishcomprehensivecancercenter
AT vazquezsilvia realworldefficacyandsafetyoferibulininadvancedandpretreatedher2negativebreastcancerinaspanishcomprehensivecancercenter
AT castanyroser realworldefficacyandsafetyoferibulininadvancedandpretreatedher2negativebreastcancerinaspanishcomprehensivecancercenter
AT villanuevarafael realworldefficacyandsafetyoferibulininadvancedandpretreatedher2negativebreastcancerinaspanishcomprehensivecancercenter
AT recaldesabela realworldefficacyandsafetyoferibulininadvancedandpretreatedher2negativebreastcancerinaspanishcomprehensivecancercenter
AT perezvalentinavarro realworldefficacyandsafetyoferibulininadvancedandpretreatedher2negativebreastcancerinaspanishcomprehensivecancercenter
AT gilgilmiguel realworldefficacyandsafetyoferibulininadvancedandpretreatedher2negativebreastcancerinaspanishcomprehensivecancercenter
AT pernassonia realworldefficacyandsafetyoferibulininadvancedandpretreatedher2negativebreastcancerinaspanishcomprehensivecancercenter